

Resource Summary Report

Generated by [NIF](#) on Jul 31, 2026

CD14

RRID:AB_2739154

Type: Antibody

Proper Citation

BD Biosciences Cat# 565283, RRID:AB_2739154

Antibody Information

URL: http://antibodyregistry.org/AB_2739154

Proper Citation: BD Biosciences Cat# 565283, RRID:AB_2739154

Target Antigen: CD14

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD14

Description: This monoclonal targets CD14

Target Organism: baboon, cynomolgus, rhesus, dog, human

Clone ID: M5E2

Antibody ID: AB_2739154

Vendor: BD Biosciences

Catalog Number: 565283

Record Creation Time: 20250820T052446+0000

Record Last Update: 20250820T213055+0000

Ratings and Alerts

No rating or validation information has been found for CD14.

No alerts have been found for CD14.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Bastos J, et al. (2025) Monocytes can efficiently replace all brain macrophages and fetal liver monocytes can generate bona fide SALL1+ microglia. *Immunity*, 58(5), 1269.

Koh DI, et al. (2024) The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy. *Cancer immunology research*, 12(4), 491.

Jacob-Dolan C, et al. (2024) B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S. *iScience*, 27(5), 109716.

Ahmed A, et al. (2023) BCG revaccination in adults enhances pro-inflammatory markers of trained immunity along with anti-inflammatory pathways. *iScience*, 26(10), 107889.

Takano T, et al. (2022) Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine. *Cell reports. Medicine*, 3(5), 100631.

Dijkman K, et al. (2021) Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection. *Cell reports. Medicine*, 2(1), 100187.

Nabet BY, et al. (2020) Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. *Cell*, 183(2), 363.